吳霞
(上海市靜安區(qū)中心醫(yī)院內(nèi)分泌科 上海 200040)
近年來,隨著對糖尿病發(fā)病機(jī)制的不斷研究與認(rèn)識,腸促胰島素(incretin)因可促進(jìn)β細(xì)胞復(fù)制和再生、抑制其凋亡以及改善α細(xì)胞功能而成為研究熱點(diǎn)。腸促胰島素是一組胃腸激素,主要包括胰高血糖素樣肽-1(glucagon-like peptide-1, GLP-1)和葡萄糖依賴性促胰島素 肽(glucose-dependent insulinotropic peptide, GIP)[1]。因?yàn)镚LP-1會被GLP-1降解酶二肽基肽酶-4(dipeptidyl peptidase-4, DPP-4)迅速降解且2型糖尿病患者體內(nèi)或多或少都存在GLP-1水平降低的現(xiàn)象,所以注射GLP-1受體激動劑和口服DPP-4抑制劑能夠促進(jìn)胰島素分泌和維持血糖水平穩(wěn)定[2]。本文簡要介紹這兩類基于腸促胰島素的抗糖尿病藥物的發(fā)展概況。
艾塞那肽是人工合成的含有39個氨基酸的exendin-4類似物,是美國批準(zhǔn)的第一個GLP-1受體激動劑。exendin-4是自希拉毒蜥(Gila monster)的唾液中分離得到的,與人GLP-1在氨基酸序列上具有53%的同源性[3]。exendin-4不是DPP-4的底物,不會被迅速降解。艾塞那肽能夠激活GLP-1受體、由此發(fā)揮類似人GLP-1的作用,但因其N端不能被DPP-4降解,故血漿半衰期更長。皮下給予艾塞那肽后約2 h達(dá)血藥濃度峰值,半衰期為2.4 h,降血糖時間超過8 h,主要由腎小球?yàn)V過清除[4]。研究證實(shí),艾塞那肽能改善2型糖尿病患者的第一時相胰島素分泌[3]和抑制餐后胰高血糖素分泌,顯著降低空腹和餐后血糖水平、顯著延緩胃排空時間[5]。與安慰劑相比,每日2次皮下注射艾塞那肽5或10 μg可降低糖化血紅蛋白A1C(glycosylated hemoglobin A1C, HbA1C)值1.0個百分點(diǎn)且長期治療有效(3年后降低HbA1C值仍為1.0個百分點(diǎn))[6],同時明顯減輕患者的體重(最多減輕3.1 kg)[7]并能使患者發(fā)生心血管事件的風(fēng)險較不使用艾塞那肽治療者降低16%[8]。歐盟最近還批準(zhǔn)了艾塞那肽的一種新劑型,即艾塞那肽每周1次用長效劑型。
艾塞那肽的常見不良反應(yīng)為惡心和嘔吐,通常發(fā)生在治療早期。根據(jù)患者個體差異調(diào)整艾塞那肽的劑量、注射時間以及選擇非工作日開始首次注射有助于減少此藥的惡心、嘔吐發(fā)生率;采用逐漸加大用藥劑量的方法能改善患者的耐受性[9]。
利拉魯肽是另一個已被批準(zhǔn)用于臨床的GLP-1受體激動劑,其結(jié)構(gòu)與人GLP-1具有97%的同源性,故也被稱為人GLP-1類似物。利拉魯肽可與血清白蛋白結(jié)合、然后緩慢釋放到循環(huán)中,能抵抗DPP-4的分解、延遲吸收和減少腎臟清除,半衰期長達(dá)12 h[10-11]。因此,利拉魯肽僅需每天注射1次。無論是單用還是聯(lián)用其他抗糖尿病藥物,利拉魯肽均能有效降低HbA1C值(1.0個百分點(diǎn)左右)和減輕患者體重[12-14],并顯著改善2型糖尿病患者的餐后血糖水平、抑制餐后胰高血糖素分泌以及顯著改善胰島素原/總胰島素比值和胰島β細(xì)胞分泌功能指數(shù)(homeostasis model assemsment of islet beta-cell function, HOMA-β)[15]。
利拉魯肽的常見不良反應(yīng)是惡心,但發(fā)生率較艾塞那肽低并會隨用藥時間延長而降低。
他司魯肽是長效人GLP-1類似物,與人GLP-1具有93%的同源性。他司魯肽因結(jié)構(gòu)中第8和第35位氨基酸被替換為氨基異丁酸、同時還含有一種能保證其緩釋性能的成分[16],故僅需每周注射1次。他司魯肽現(xiàn)尚處于臨床試驗(yàn)階段,但已完成的II期和III臨床試驗(yàn)顯示,每周注射10或20 mg、或每2周注射20 mg他司魯肽均能有效降低HbA1C值和體重,尤以降低空腹血糖水平的作用最為顯著[17-18]。他司魯肽的不良反應(yīng)主要是惡心、嘔吐以及注射部位的過敏反應(yīng)[18]。
lixisenatide是經(jīng)對exendin-4結(jié)構(gòu)中C末端的6個賴氨酸殘基進(jìn)行修飾后得到的一個GLP-1類似物,能耐受DPP-4的降解,可一日1次皮下注射用藥。與安慰劑相比,lixisenatide能顯著降低HbA1C值、尤其是降低餐后2 h時的血糖水平,但不會引起低血糖反應(yīng)[19-20]。lixisenatide已完成III期臨床試驗(yàn),主要不良反應(yīng)是胃腸道癥狀如惡心、嘔吐等。
如阿必魯肽(albiglutide)、(Val8)GLP-1、(His7)GLP-1和BMI51077等,目前也都處在臨床前研發(fā)或臨床試驗(yàn)階段。
DPP-4抑制劑通過抑制DPP-4活性而提高人體內(nèi)天然GLP-1和GIP的濃度,由此刺激胰島素分泌和抑制胰高血糖素分泌并最終達(dá)到控制血糖水平的目的。
西格列汀是首個獲準(zhǔn)上市的DPP-4抑制劑,是含三氮唑并哌嗪環(huán)的β-氨基酸衍化物[21],人口服后吸收迅速、1~4 h達(dá)血藥濃度峰值,主要以原形從腎臟代謝,血漿半衰期為11.8~14.4 h,可每日1次用藥[22]。無論單用還是聯(lián)用雙胍類、磺酰脲類或噻唑烷二酮類抗糖尿病藥物,西格列汀均能顯著降低2型糖尿病患者的HbA1C值(降低0.5~0.79個百分點(diǎn))以及空腹血糖和餐后2 h時的血糖水平[23-25],且低血糖發(fā)生率低、無體重增加風(fēng)險。
西格列汀的不良反應(yīng)包括超敏反應(yīng)、肝酶水平升高、上呼吸道感染、鼻咽炎和頭痛等。
維格列汀是α-氨基?;杌量┩檠苌?,是一種選擇性的DPP-4競爭性抑制劑,具有較高的酶抑制活性。維格列汀被人口服后吸收迅速,約1.1 h達(dá)血藥濃度峰值,主要從腎臟代謝,血漿半衰期為1.7~2.5 h,需每日2次用藥。維格列汀能促進(jìn)葡萄糖刺激的胰島素分泌和抑制餐后胰高血糖素分泌,進(jìn)而降低血糖、特別是餐后血糖水平[26-27]。維格列汀聯(lián)用二甲雙胍能提高2型糖尿病患者的β細(xì)胞功能及餐后胰島素的敏感度[28],聯(lián)用吡格列酮能更有效地降低HbA1C值且不會提高低血糖的發(fā)生率[29]。
維格列汀的最常見不良反應(yīng)是頭痛、鼻咽炎、咳嗽、便秘、頭暈和出汗量增加等。維格列汀在動物實(shí)驗(yàn)中見有皮膚壞死和腎損害等不良反應(yīng),但在臨床研究中未出現(xiàn)過。
沙格列汀是在維格列汀的氰基吡咯烷結(jié)構(gòu)上引入環(huán)丙基、從而提高了氰基吡咯烷的穩(wěn)定性后得到的,人口服后吸收迅速、約2 h達(dá)血藥濃度峰值,主要從腎臟和肝臟代謝,血漿半衰期為2.1 h,但其抑制DPP-4活性的時間可達(dá)24 h,故僅需每日1次用藥。沙格列汀的臨床療效與西格列汀相當(dāng),每日1次口服5 mg沙格列汀可降低HbA1C值0.45~0.63個百分點(diǎn)[30],聯(lián)用二甲雙胍則可使HbA1C值降低0.69個百分點(diǎn)[31]。
沙格列汀的最常見不良事件為上呼吸道感染、尿路感染和頭痛。
利格列汀是首個主要經(jīng)膽道和胃腸道代謝的DPP-4抑制劑,用藥劑量中僅有5%由腎臟代謝,用于腎功能損害患者時不需調(diào)整劑量。利格列汀每日1次5 mg治療可降低HbA1C值0.4~0.7個百分點(diǎn)[32],聯(lián)用二甲雙胍可使HbA1C值額外再降低0.4~0.6個百分點(diǎn)[33]。
阿格列汀現(xiàn)僅在日本獲準(zhǔn)上市,口服后1~2 h達(dá)血藥濃度峰值,主要由腎臟代謝。阿格列汀可顯著改善2型糖尿病患者的血糖控制水平[34],但長期安全性尚有待臨床實(shí)踐和臨床研究的考察。阿格列汀的最常見不良反應(yīng)包括鼻咽炎、泌尿道感染、頭痛、上呼吸道感染和外周水腫。
如地格列汀(denagliptin)、卡格列?。╟armegliptin)、美格列?。╩elogliptin)和度格列?。╠utogliptin)等,但目前還都處在不同的研發(fā)階段。
綜上所述,GLP-1受體激動劑和DPP-4抑制劑因能有效降低血糖水平、改善胰島細(xì)胞功能、安全性和耐受性良好并有可減輕或不增加體重、極少導(dǎo)致低血糖和嚴(yán)重不良反應(yīng)等優(yōu)點(diǎn),為2型糖尿病治療提供了新的手段。另有一些研究發(fā)現(xiàn),這兩類藥物也有對心血管的潛在益處。但是,由于目前基于腸促胰島素的抗糖尿病藥物在臨床應(yīng)用的時間尚短,期待有更多的臨床研究證實(shí)其長期的治療效果和安全性。
參考文獻(xiàn)
[1] Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes [J]. Diabetes Care, 2003, 26(10): 2929-2940.
[2] Nauck M, Stockmann F, Ebert R,et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes [J]. Diabetologia,1986, 29(1): 46-52.
[3] Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes [J]. Regul Pept,2004, 117(2): 77-88.
[4] Kolterman OG, Kim DD, Shen L,et al. Pharmacokinetics,pharmacodynamics,and safety of exenatide in patients with type 2 diabetes mellitus [J]. Am Health Syst Pharm, 2005,62(2): 173-181.
[5] Kolterman OG, Buse JB, Fineman MS,et al. Synthetic exendin-4 (exenatide) signi fi cantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes [J]. J Clin Endocrinal Metab, 2003, 88(7): 3082-3089.
[6] Klonoff DC, Buse JB, Nielsen LL,et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years [J]. Curr Med Res Opin, 2008, 24(1): 275-286.
[7] Moretto TJ, Milton DR, Ridge TD,et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study [J]. CIin Ther, 2008, 30(8): 1448-1460.
[8] Best JH, Hoogwerf BJ, Herman WH,et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the lifeline database [J].Diabetes Care, 2011, 34(1): 90-95.
[9] Fineman MS, Shen LZ, Taylor K,et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes [J]. Diabetes Metab Res Rev, 2004, 20(5): 411-417.
[10] Vilsboll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus [J]. Expert Opin lnvestig Drugs, 2007, 16(2): 231-237.
[11] 褚建平. 腸促胰島素類制劑及二肽基肽酶抑制物的研究與臨床應(yīng)用進(jìn)展[J]. 現(xiàn)代實(shí)用醫(yī)學(xué), 2009, 21(12): 1276-1279.
[12] Marre M, Shaw J, Brandle M,et al. Liraglutide, a oncedaily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) [J]. Diabet Med, 2009, 26(3): 268-278.
[13] Nauck M, Frid A, Hermansen K,et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus(LEAD-2 Met) [J]. Diabetes Care, 2009, 32(1): 84-90.
[14] Zinman B, Gerich J, Buse JB,et al. Efficacy and safety ofthe human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus(LEAD-4 Met + TZD) [J]. Diabetes Care, 2009, 32(7): 1224-1230.
[15] Degn KB, Juhl CB, Sturis J,et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide(NN2211) markedly improves 24h glycemia and alpha- and betacell function and reduces endogenous glucose release in patients with type 2 diabetes [J]. Diabetes, 2004, 53(5): 1187-1194.
[16] Dong JZ, Shen Y, Zhang J,et al. Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes [J]. Diabetes Obes Metab, 2011,13(1): 19-25.
[17] Nauck MA, Ratner RE, Kapitza C,et al. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone:a double-blind placebo-controlled study [J]. Diabetes Care,2009, 32(7): 1237-1243.
[18] Henry RR, Mudaliar S, Kanitra L,et al. Ef fi cacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks:T-Emerge 3 Trial [J]. J Clin Endocrinol Metab, 2012, 97(7):2370-2379.
[19] Fonseca VA, Alvarado-Ruiz R, Raccah D,et al. Ef fi cacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono) [J].Diabetes Care, 2012, 35(6): 1225-1231.
[20] Seino Y, Min KW, Niemoeller E,et al. Randomized, doubleblind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia) [J]. Diabetes Obes Metab, 2012, 14(10): 910-917.
[21] Kim HJ, Kwak WY, Min JP,et al. Discovery of DA-1229:a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes [J]. Bioorg Med Chem Lett, 2011,21(12): 3809-3812.
[22] Bergman AJ, Stevens C, Zhou Y,et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin,a dipeptidyl peptidase-IV inhibitor: a doubleblind, randomized, placebo-controlled study in healthy male volunteers [J]. Clin Ther, 2006, 28(1): 55-72.
[23] Aschner P, Kipnes MS, Lunceford JK,et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [J]. Diabetes Care, 2006, 29(12): 2632-2637.
[24] Hermansen K, Kipnes M, Luo E,et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled glimepiride alone or on glimepiride and metformin [J].Diabetes Obes Metab, 2007, 9(5): 733-745.
[25] Rosenstock J, Brazg R, Andryuk PJ,et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin add to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week,multicenter, randomized, double-blind, placebo-controlled,parallel-group study [J]. Clin Ther, 2006, 28(10): 1556-1568.
[26] Ahren B, Landin-Olsson M, Jansson PA,et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels,and reduces glucagon levels in type 2 diabetes [J]. J Clin Endocrinol Metab, 2004, 89(5): 2078-2084.
[27] Pratley R, Galbreath E. Twelve-week monotherapy with the DPP-4 inhibitor, LAF237 improves glycemic control in patients with type 2 diabetes [J]. Diabetes, 2004, 53(Suppl 2): A8.
[28] Ahren B, Gomis R, Standl E,et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase-4 inhibitor LAF237 in metformin-treated patients with type 2 diabetes [J]. Diabetes Care, 2004, 27(12): 2874-2880.
[29] Richter B, Bandeira-Echtler E, Bergerhoff K,et al.Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus [J/OL]. Cochrane Database Syst Rev, 2008, (2):CD006739 [2010-02-24]. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006739.pub2/pdf.
[30] Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-na?ve patients with type 2 diabetes [J]. Diabetes Obes Metab, 2008,10(5): 376-386.
[31] DeFronzo RA, Hissa MN, Garb AJ,et al. The efficacy and safety of saxagliptin when add on to metformin therapy in patients with inadequately controlled type 2 diabetes with mefformin alone [J]. Diabetes Care, 2009, 32(9): 1649-1655.
[32] Karen W, Sando KR. Linagliptin (Tradjenta) for the treatment of diabetes mellitus [J]. Am Fam Physician, 2012, 86(12):1144-1148.
[33] Lajara R. Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes [J].Expert Opin Pharmacother, 2012, 13(18): 2663-2671.
[34] Fleck P, Christopher R, Covington P,et al. Ef fi cacy and safety of alogliptin monotherapy over 12 weeks in patients with type 2 diabetes [J]. Diabetes, 2008, 57(Suppl 1): A143.